Fatima Eltyeb Hago: Are We Doing More Harm Than Good with Combination Antithrombotic Therapy in AF?
Fatima Eltyeb Hago, Clinical Pharmacist at Dr. Sulaiman AL Habib Medical Group, shared on LinkedIn:
”Are we doing more harm than good with combination antithrombotic therapy in our AF patients?
In anticoagulated patients with atrial fibrillation, antiplatelet therapy should be the exception not the rule.
41% reduction in major bleeding with OAC alone vs. combination therapy .
(Gargiulo et al., JACC 2026 – meta-analysis of 4 RCTs, 4,092 patients)
45% of APT users in post-acute long-term care settings have no clear indication .
(Ko et al., JAMA Internal Medicine 2024)
Yet aspirin and P2Y12 inhibitors continue to be prescribed alongside anticoagulation with no reassessment, no stop dates, and no clear rationale.
This 2026 guide from the Anticoagulation Forum gives us the framework to act , verify the indication, assess the timing, and make a clear clinical decision: (deprescribe, monitor, or continue) with a defined plan.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria